The GI and obesity doctor points to about 25% weight loss in the 2,339-adult trial of people with obesity but no diabetes, and says that figure isn't the whole story.
Recap by typeshit. Post by Dr Janese Laster-Butler | GI + Obesity Medicine| DC on Instagram.
Popular Mechanics traces how her 1980s work at Mass General showed GLP-1 triggers insulin release. Gallup now puts GLP-1 weight loss use at about 11% of Americans.
Barzilai highlights trial results on retatrutide in adults with sleep apnea and obesity or overweight, a new use being tested for Lilly's drug.
The Washington meeting runs November 14 to 17, with primary REDEFINE 9 results and pediatric semaglutide research for kids 6 to under 12.
Researchers tracked spending on drinks while out and found a sharp drop among people taking GLP-1 medications.
EASD data showed Lilly's EloraTZP combo cut 23% of body weight. Zealand's petrelintide trial lead says nausea ran at under half the usual GLP-1 rate.
16:32
Dr. Kevin Joseph, DO, who treats liver disease daily, shares his views on peptides. The claims are his own, not established treatment guidance.
Loading…